Skip to content
Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences

Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences

  • Post published:March 14, 2023
  • Post category:Press Release
Read more about the article Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board

Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board

  • Post published:March 14, 2023
  • Post category:Press Release
Read more about the article BetterLife Closes $1,857,143 of Private Placement

BetterLife Closes $1,857,143 of Private Placement

  • Post published:March 14, 2023
  • Post category:Press Release
Read more about the article Reunion Neuroscience Files Lawsuit Against Mindset Pharma

Reunion Neuroscience Files Lawsuit Against Mindset Pharma

  • Post published:March 13, 2023
  • Post category:Press Release
Read more about the article BetterLife Files Amended and Restated Offering Document for Offering of Units

BetterLife Files Amended and Restated Offering Document for Offering of Units

  • Post published:March 11, 2023
  • Post category:Press Release
Read more about the article Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”

Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”

  • Post published:March 9, 2023
  • Post category:Press Release
Read more about the article BetterLife Announces Pricing of Proposed Offering of Units

BetterLife Announces Pricing of Proposed Offering of Units

  • Post published:March 8, 2023
  • Post category:Press Release
Read more about the article Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

  • Post published:March 8, 2023
  • Post category:Press Release
Read more about the article BetterLife Announces Offering of Units

BetterLife Announces Offering of Units

  • Post published:March 8, 2023
  • Post category:Press Release
Read more about the article Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry

Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry

  • Post published:March 7, 2023
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2026, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More